

TÍTULO	REVISTA	FI	Q/D
Characterization of HMGB1/2 Interactome in Prostate Cancer by Yeast Two Hybrid Approach: Potential Pathobiological Implications	CANCERS	6,162	Q1
Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution	BREAST CANCER-TARGETS AND THERAPY		
Lung cancer in Spanish women: The WORLD07 project	EUROPEAN JOURNAL OF CANCER CARE	2,421	D1
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2	JOURNAL OF CLINICAL ONCOLOGY	28,349	D1
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping	ANNALS OF ONCOLOGY	14,196	D1
Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer	THROMBOSIS AND HAEMOSTASIS	4,733	Q1
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion	EUROPEAN JOURNAL OF CANCER	6,680	Q1

Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study	SCIENTIFIC REPORTS	4,011	Q1
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/EI Alamo Registry)	SCIENTIFIC REPORTS	4,011	Q1
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors	CANCER IMMUNOLOGY IMMUNOTHERAPY	4,900	Q1
Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)	TRANSLATIONAL LUNG CANCER RESEARCH	4,806	Q1
Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy	TRANSLATIONAL LUNG CANCER RESEARCH	4,806	Q1
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance	LUNG CANCER	4,599	Q1
Efficacy and safety of FOLFIRI/afibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers	CANCER MEDICINE	3,357	Q2
Development and validation of a sexual relations satisfaction scale in patients with breast cancer - "SEXSAT-Q"	HEALTH AND QUALITY OF LIFE OUTCOMES	2,318	Q2

Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study	BREAST CANCER RESEARCH AND TREATMENT	3,471	Q2
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial	CANCER CHEMOTHERAPY AND PHARMACOLOGY	3,008	Q2
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study	BREAST CANCER RESEARCH AND TREATMENT	3,471	Q2
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothed or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study	INVESTIGATIONAL NEW DRUGS	2,663	Q2
SEOM clinicalguidelines to primary prevention of cancer (2018)	CLINICAL & TRANSLATIONAL ONCOLOGY	2,441	Q3

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	BMC CANCER	2,933	Q3
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)	CLINICAL & TRANSLATIONAL ONCOLOGY	2,441	Q3
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)	CLINICAL & TRANSLATIONAL ONCOLOGY	2,441	Q3
Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study	CLINICAL BREAST CANCER	2,762	Q3
Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists	JOURNAL OF DRUG ASSESSMENT		